From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer

Published:2019 Issue:5 Volume:4 Page:e000548
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Pirker Robert^ORCID,Filipits Martin^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

2. Chemotherapy: advanced NSCLC--should we use doublets in elderly patients?;Pirker;Nat Rev Clin Oncol,2011

3. Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key;Pirker;Ann Transl Med,2019

4. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

5. Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: the INSIGHT study;Ramlau;J Thorac Oncol,2015

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer;Lung Cancer;2024-09

2. Long non-coding RNAs; potential contributors in cancer chemoresistance through modulating diverse molecular mechanisms and signaling pathways;Pathology - Research and Practice;2024-08

3. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles;Journal of Translational Medicine;2024-03-03

4. Drug-Induced Liver Injury Associated with Alk Inhibitors: A Pharmacovigilance Analysis of the Fda Adverse Event Reporting System (Faers);2024

5. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events;Future Oncology;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3